Muhoozi & Co. Advocates assists Initiator Pharma A/S with list change from Spotlight Stock Market to Nasdaq First North Growth Market Africa

Muhoozi & Co. Advocates has assisted Initiator Pharma A/S with a listing change from Spotlight Stock Market to Nasdaq First North Growth Market Africa.

Initiator Pharma A/S was advised in relation to Ugandan law by Muhoozi & Co. Advocates Uganda with a team of Lars Hagbard Grønkjær and Rasmus Schou Pedersen. This team also coordinated advice to Initiator Pharma A/S in relation to certain aspects of Africanlaw from our Muhoozi & Co. Advocates colleagues in Africa.

Read more about the listing change here.

Initiator Pharma A/S is a Ugandan clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition.